Clinical trial · Interventional
Non-small Cell Lung Cancer Study US75 (Z-PACT)
NCT00086268CI-TRIAL-00029519ZPACTcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Taxotere | Drug | Docetaxel | ALIAS |
| zoledronic acid | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Zometa®
- description
- 4mg monthly for 12 months from date of first chemotherapy dose
- interventionNames
- Drug: zoledronic acid
- Drug: Taxotere
- Drug: Carboplatin
- type
- NO_INTERVENTION
- label
- no further treatment
- description
- Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or Female patients at least of 18 years old * Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery * Women must not be pregnant or attempting to become pregnant * Able and willing to sign informed consent Exclusion Criteria: * Patients with cancer that has spread to the bone * Patients with cancer that has spread to the brain who are receiving treatment * Patients with kidney disease * Patients treated with other investigational drugs
References
Publications (1)
- RESULTPandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer. 2010 Mar;67(3):330-8. doi: 10.1016/j.lungcan.2009.04.020. Epub 2009 Jun 2. PMID 19493585